<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00126373</url>
  </required_header>
  <id_info>
    <org_study_id>CGO10410022</org_study_id>
    <nct_id>NCT00126373</nct_id>
  </id_info>
  <brief_title>A Trial of Wellbutrin for Crohn's Disease</brief_title>
  <official_title>A Randomized Controlled Trial of Wellbutrin for Crohn's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Altschuler, Eric, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Altschuler, Eric, M.D.</source>
  <brief_summary>
    <textblock>
      The investigators are testing the hypothesis that Wellbutrin (bupropion) can give a clinical&#xD;
      remission in Crohn's disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Wellbutrin (bupropion) is approved for use as an antidepressant. There have been some cases&#xD;
      in which people on Wellbutrin had significant improvement clinically in their Crohn's&#xD;
      disease. In this trial, the hypothesis that Wellbutrin can induce clinical remission in&#xD;
      Crohn's disease will be tested. The investigators will also be looking to see if Wellbutrin&#xD;
      can lower levels of the inflammatory cytokine tumor necrosis factor-alpha (TNF).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">March 2006</completion_date>
  <primary_completion_date type="Actual">March 2006</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with Crohn's disease activity index (CDAI) &lt; 150 at the end of twelve weeks</measure>
    <time_frame>0, 2, 4, 8, 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with CDAI drop of at least 70 points at the end of twelve weeks</measure>
    <time_frame>0, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time course of CDAI</measure>
    <time_frame>0, 2, 4, 8, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of drug and/or placebo on tumor necrosis factor-alpha (TNF) levels</measure>
    <time_frame>0, 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Crohn Disease</condition>
  <arm_group>
    <arm_group_label>Sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (sugar) pill with identical look to bupropion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>buproprion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>bupropion pill</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Wellbutrin (bupropion)</intervention_name>
    <description>bupropion 150mg-300mg daily</description>
    <arm_group_label>Sugar pill</arm_group_label>
    <arm_group_label>buproprion</arm_group_label>
    <other_name>Wellbutrin, bupropion</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Moderate to severe Crohn's disease with 220 &lt; CDAI &lt; 400.&#xD;
&#xD;
          -  All patients in the study must have not had any anti-TNF antibodies for at least eight&#xD;
             weeks.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients will be excluded from the study if they have fulminant Crohn's disease&#xD;
             requiring parenteral steroid treatment, hospitalization, or need of surgery&#xD;
             imminently.&#xD;
&#xD;
          -  Patients with serious infections in the preceding three months, opportunistic&#xD;
             infections within one month, or current signs or symptoms of severe, progressive or&#xD;
             uncontrolled renal, hepatic, hematologic, endocrine, pulmonary, cardiac, neurological,&#xD;
             or cerebral disease will be excluded.&#xD;
&#xD;
          -  Patients will also be excluded from the study if they have a history of a seizure,&#xD;
             epilepsy, presumed current central nervous system tumor, have or have had anorexia&#xD;
             nervosa or bulimia, are currently taking or have taken in the last four weeks any drug&#xD;
             in the monoamine oxidase inhibitor class, or are allergic to Wellbutrin.&#xD;
&#xD;
          -  Patients with active major depression or suicidal ideation will be excluded, as will&#xD;
             patients with a score of 19 or higher on the Beck depression inventory.&#xD;
&#xD;
          -  Patients will be excluded if they are currently or have taken a medicine in the&#xD;
             selective serotonin reuptake class, mirtazapine, venlafaxine, a tricyclic&#xD;
             antidepressant, a mood stabilizing, or antipsychotic medication in the previous two&#xD;
             weeks.&#xD;
&#xD;
          -  Patients will be excluded if they are currently abusing alcohol or have alcohol&#xD;
             dependence.&#xD;
&#xD;
          -  Patients will be excluded from the study if their baseline liver function tests are&#xD;
             greater than twice the upper limit of normal, or if a clinical investigator believes&#xD;
             that their baseline chemistry, liver function tests or complete blood count&#xD;
             contraindicates entry into the study.&#xD;
&#xD;
          -  Pregnant or lactating females are excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric L Altschuler, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mt. Sinai Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mt. Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <study_first_submitted>August 2, 2005</study_first_submitted>
  <study_first_submitted_qc>August 2, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2005</study_first_posted>
  <last_update_submitted>January 19, 2012</last_update_submitted>
  <last_update_submitted_qc>January 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Crohn disease</keyword>
  <keyword>TNF-alpha</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupropion</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

